Thyroid cancer rates are up worldwide. Total thyroidectomy rates are declining.
Explore This Issue
February 2025This apparent dichotomy is driven by two trends: increased diagnosis of thyroid cancer, largely due to increased availability and utilization of advanced imaging, and technological advances that enable physicians to treat thyroid cancers and nodules more precisely.
Over the past three decades, the incidence of thyroid cancer has “increased dramatically,” according to the American Thyroid Association (Clinical Thyroidology. https://tinyurl.com/2a6k996m). Thyroid cancer rates have tripled in the UK since the 1990s (Cancer Research UK. https://tinyurl.com/yefx6pmf); in the U.S., rates of thyroid cancer were growing faster than any other cancer until physicians adopted stricter diagnostic criteria in the mid-2010s (American Cancer Society. https://tinyurl.com/3h7vw6vx). Globally, thyroid cancer incidence is expected to increase by nearly 30%, and thyroid cancer-related mortality by 67%, by 2040 (Indian J Surg Oncol. doi:10.1007/s13193-021-01429-y).
In some parts of the world, likely overdiagnosis of thyroid cancer has led to an increase in the number of thyroidectomy procedures (Cancers (Basel).doi:10.3390/cancers15112931). In the U.S. and elsewhere, there’s been a “significant scaling back on how much thyroid surgery is done,” said David C. Shonka, Jr., MD, associate professor of otolaryngology–head and neck surgery at the University of Virginia School of Medicine in Charlottesville, as providers increasingly recognize the impact of surgical morbidity on patients’ quality of life.
“When I initially trained in thyroid surgery, surgeons were still using big incisions and removing the entire thyroid for small cancers,” Dr. Shonka said. “Now, we’re using smaller incisions and doing less surgery in general.”
Otolaryngologists today have more options than ever to safely manage thyroid cancers and nodules. Here is a look at the major advancements revolutionizing thyroid surgery.
New Approaches to Thyroid Surgery
One of the biggest shifts in the surgical management of thyroid disease has been the move toward performing as little surgery as possible. A “modest but significant increase” in lobectomy rates followed the release of the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update; however, the majority (82%) of patients with eligible papillary thyroid carcinoma were still treated with total thyroidectomy (Endocr Oncol.doi:10.1530/EO-22-0095). A retrospective study of surgical management practices at high-volume centers noted a significant shift in management from 2010 to 2018—the percentage of patients with likely malignant thyroid nodules and no clinical evidence of further diseases treated with total thyroidectomy plus prophylactic neck dissection decreased from 50% to 10%. The proportion of patients with likely malignant modules treated with thyroid lobectomy increased from 2% to 19%, and diagnostic thyroidectomies in patients with cytologically indeterminate nodules decreased from 67% to 35% (Thyroid. doi:10.1089/thy.2019.0783).
The move toward less surgery has likely been “a big benefit to patients,” Dr. Shonka said, as morbidity related to thyroid removal can significantly affect patients’ quality of life for decades.
Patients who need thyroid surgery but wish to avoid a scar on their neck can now choose remote-access thyroid surgery, at least at some institutions. Options include the trans-axillary approach, the bilateral axilla-breast approach, and natural orifice (transoral) surgery.
Although these methods have been described as minimally invasive techniques (Cancers (Basel). doi:10.3390/cancers15112931), remote access thyroid surgeries are complex and typically take significantly longer than traditional thyroid surgery. Costs may be higher due to the cost of equipment and increased operative time. Additional complications—such as brachial plexus injury—can occur, depending on the approach (Indian J Surg Oncol. doi.org/10.1007/s13193-021-01364-y).
We don’t potentially put the good nerve at risk; we can stage the other side if we are concerned that we have a nerve injury on one side, and come back another day. —Vaninder Dhillon, MD
Robotic transoral thyroid surgery is not commonly done in the U.S. Dr. Shonka doesn’t perform it; neither does Vaninder Dhillon, MD, assistant professor of otolaryngology–head and neck surgery at Johns Hopkins University School of Medicine and Johns Hopkins Otolaryngology–Head and Neck Surgery in Bethesda, Md.
“I trained in a place where a lot of transoral surgery was done, but I have not adopted it into my practice,” Dr. Dhillon said. “But I do offer it to my patients because some of my colleagues do it. If a scar is a reason a patient doesn’t want to do surgery, I encourage them to meet with one of my colleagues, because a scar can be avoided.”
Although transoral surgery has been around for some time, it seems to have had a fairly limited impact in the U.S. and has not been incorporated in some major cancer centers, according to Gregory W. Randolph, MD, professor of otolaryngology–head and neck surgery and the Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology at Harvard Medical School in Boston.
Intra-Operative Nerve Monitoring
In contrast, nerve monitoring is a transformative technology that is now routinely applied in thyroid and parathyroid surgery, with a 2022 editorial in the Journal of Clinical Medicine calling it “the gold standard to reduce post-thyroidectomy voice complications” (J Clin Med.doi:10.3390/jcm11237233).
Much as a Doppler allows vascular surgeons to assess the movement of blood through a vessel, intra-operative nerve monitoring (IONM) allows physicians to assess the function of crucial nerves—typically, the recurrent laryngeal nerve (RLN)—during thyroid surgery.
“You can test, in real-time, the integrity of the recurrent laryngeal nerves during the operation,” Dr. Shonka said. Because the technology measures the electrical activity of the nerve, physicians can detect negative changes and adapt surgery to prevent additional harm. So, if IONM reveals impaired function of the right RLN, the surgeon can stage and delay surgery on the other side until a future date.
“We don’t potentially put the good nerve at risk; we can stage the other side if we are concerned that we have a nerve injury on one side, and come back another day,” Dr. Dhillon said.
Research to date suggests that IONM decreases morbidity and improves patient outcomes and quality of life. A review of nearly 5,500 cases found that when surgeons routinely used nerve monitoring during thyroid cancer surgery, the incidence of vocal cord dysfunction was 2.4% in the short term and 2.2% in the long term, compared to 4.4% and 3.7%, respectively. Routine use of IONM was independently associated with a decreased risk of short- and long-term vocal cord dysfunction, a lower risk of post-op hypoparathyroidism, and a higher likelihood of same-day discharge (BMC Surg. doi:10.1186/s12893-023-02122-3).
Like every technology, the utility of IONM depends, in part, on the skill and knowledge of the one using it. Intermittent nerve monitoring, for instance, is more useful if it’s done frequently throughout surgery, as opposed to sporadically. (Continuous nerve monitoring systems are available, but “much less utilized,” Dr. Randolph and others said.) Real-world use of IONM is still selective. According to the 2014 to 2021 Collaborative Endocrine Surgery Quality Improvement Program thyroidectomy and parathyroidectomy datasets, surgeons are more likely to use IONM during thyroid surgery than parathyroid surgery. Those who routinely use IONM during thyroidectomy are more likely to use the technology during parathyroidectomies, but there is a 43% decrease in the routine use of IONM between thyroidectomy and parathyroidectomy (Surgery. doi:10.1016/j.surg.2023.11.024).
Increasingly, surgeons are using IONM to monitor the external branch of the superior laryngeal nerve (EBSLN) during surgery as well. The EBSLN innervates the cricothyroid muscle, which impacts vocal pitch and projection, so proper functioning of the nerve is particularly important to singers and other people who use their voices professionally. Because damage to the EBSLN can cause significant morbidity, Amanda L. Silver Karcioglu, MD, clinical assistant professor at the University of Chicago Pritzker School of Medicine, monitors it routinely.
“When I was in residency, it was not a nerve we routinely monitored,” she said. “Now that we can, I monitor it in every case when I’m working near the superior pole of the thyroid.” Doing so doesn’t require any additional tools, as the same technology that’s used to monitor the RLN can be used on the EBSLN.
EBSLN monitoring isn’t yet widespread. Just 11% of surveyed Spanish endocrine surgeons report stimulation of EBLSN during all thyroidectomies, even though 78% monitor the RLN during all thyroidectomies (Sci Rep. doi:10.1038/s41598-024-68230-z). It is unknown how common EBSLN monitoring is in the U.S.
Targeted application of IONM during thyroid and parathyroid surgeries, including increased use of EBSLN monitoring, may further decrease surgical morbidity and enhance patients’ quality of life.
“Nerve monitoring overall is now widely disseminated, but there’s still a long way to go to make sure that people are getting all they can out of nerve monitoring,” Dr. Randolph said.
Parathyroid Identification
Hypocalcemia due to inadvertent parathyroid damage is one of the most common complications of thyroidectomy. Research from Sweden and elsewhere suggests that the risk of permanent hypocalcemia after total thyroidectomy is higher than previously understood—and may be underestimated (Br J Surg. doi:10.1093/bjs/znad366; Ann Surg. 2021. doi: 10.1097/SLA.0000000000003800). Research has also shown widespread effects of hypocalcemia on the body and patients’ quality of life. A 2023 meta-analysis of 81 studies found that hypoparathyroidism is associated with an increased risk of cataracts (with prevalence rates ranging from 27% to 55%), neuropsychiatric sequelae (including depression and seizures), and cardiac arrhythmias (Ann Thyroid. doi:10.21037/aot-22-10). Other long-term impacts of hypocalcemia include an increased risk of renal insufficiency and increased risk of any malignancy; patients with cardiovascular disease at the time of thyroidectomy also have an increased risk of cardiovascular events during follow-up (Surgery. doi: 10.1016/j.surg.2019.06.056).
“The impact on patients’ lives is actually quite substantial,” Dr. Karcioglu said.
One way to decrease the risk of hypoparathyroidism (and associated untoward effects) is to avoid unintentional removal of or damage to the parathyroids. The U.S. Food and Drug Administration granted clearance to two different parathyroid detection systems in 2018: one, probe based; and the other, camera based. Both are based on the discovery that parathyroid glands autofluoresce under near-infrared light (JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2022.4421).
“This is another example of a technology that is additive to what a surgeon’s eyes and technique provide and helps with definitive identification of parathyroid tissue,” Dr. Randolph said.
The probe-based detection system is analogous to the technology used for IONM. “If you’re used to using a probe for nerve monitoring, this is very simple and easy,” Dr. Karcioglu said. “You simply touch the tissue of interest with the probe and use a foot pedal to activate the probe and get a detection ratio, and you can do that as many times as you want during surgery.”
Because the parathyroids autofluoresce even after removal from the body, surgeons can use technology to check surgically excised matter for parathyroid tissue. “If they see a bright spot in the tissue, they may be able to reimplant parathyroid glands they’ve inadvertently removed,” Dr. Shonka said.